BRIEF-Kymera Therapeutics Completes Enrollment In The Phase 2B Broaden2 Trial Of KT-621 In Atopic Dermatitis With Topline Data By Year-End 2026

Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc.

KYMR

0.00

June 25 (Reuters) - Kymera Therapeutics Inc KYMR.O:

  • KYMERA THERAPEUTICS COMPLETES ENROLLMENT IN THE PHASE 2B BROADEN2 TRIAL OF KT-621 IN ATOPIC DERMATITIS WITH TOPLINE DATA BY YEAR-END 2026

  • KYMERA THERAPEUTICS COMPLETES ENROLLMENT IN THE PHASE 2B BROADEN2 TRIAL OF KT-621 IN ATOPIC DERMATITIS WITH TOPLINE DATA BY YEAR-END 2026

  • KYMERA THERAPEUTICS - TOPLINE DATA FOR BROADEN2 PHASE 2B TRIAL EXPECTED BY YEAR-END 2026

  • KYMERA THERAPEUTICS - PHASE 3 TRIALS IN ATOPIC DERMATITIS EXPECTED TO INITIATE BY MID-2027

  • KYMERA THERAPEUTICS - KT-621 BREADTH PHASE 2B ASTHMA TRIAL DATA EXPECTED IN LATE 2027

Source text: ID:nGNX3rD6JW

Further company coverage: KYMR.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.